Boehringer Ingelheim Gmbh

Boehringer Ingelheim Kg

Wolf D Bechtel

Karl-Heinz Weber

Claus S Schneider

Gerhard Walther

Karin Boke-Kuhn

Dietrich Arndts

Bernhard Freund

Peter Gruber

Rolf Stefan Brickl

Karin Boke

Herbert Stricker

Gerhard Bozler

Siegfried Darda

Karl L Rominger

Heribert Harwalik

Volkmar Haselbarth

Adolf Langbein

Karl-Heinz Pook

Compounds of the formula ##STR1## wherein one of R.sub.1 and R.sub.2 is hydrogen, halogen, methyl, methoxy, amino or nitro and the other is hydrogen; or

(2-phenyl-2-(pyridyl-oxy, or -thio)-ethyl)-amines and salts thereof

The invention relates to 4-phenyl-tetrahydro-furano-pyridines of the formulas ##STR1## wherein R.sup.1 to R.sup.5 are variously defined. The compounds of the invention are intended to be used as anti-depressants with, in particular, thymoleptic and central-stimulant properties.

4-phenyl-tetrahydro-furano-pyridines and anti-depressant pharmaceutical

This invention relates to a pharmaceutical dosage unit composition consisting essentially of a gelatin capsule containing (1) a disintegrating core comprising clonidine, said disintegrating core having a readily water-soluble coating, and (2) a plurality of non-disintegrating cores comprising clonidine, said non-disintegrating cores having a coating consisting of from 20 to 90 percent by weight of a water-insoluble film former and from 10 to 80 percent by weight of a water-soluble polymer, the diameter of each of the disintegrating and non-disintegrating cores being at least about 5 mm.

Retard form of pharmaceuticals with insoluble porous diffusion coatings

Compounds of the formula ##STR1## wherein R.sub.1 is amino, acetylamino, hydroxymethyl, methoxymethyl or ##STR2## R.sub.2 and R.sub.3, which may be identical to or different from each other, are each hydrogen, fluorine, chlorine, bromine, trifluoromethyl, hydroxyl, methoxy, methyl or ethyl;

4-Phenyl-4,5,6,7-tetrahydro-thieno[2,3-c]pyridines and salts thereof,

4-Phenyl-4,5,6,7-tetrahydro-thieno [2,3-c]pyridines, compositions and use

A pharmaceutical dosage unit retard form having a constant, pH-independent release rate of active ingredient, consisting of a core comprising an active ingredient, and a semi-permeable diffusion coating over the core, where the coating consists of a water-insoluble film-former, a water-soluble polymer and eventually an acid-insoluble polymer incorporated therein.

A pharmaceutical dosage unit retard form having a constant, pH-independent release rate of active ingredient, consisting of a core comprising an active ingredient, and a semi-permeable diffusion coating over the core, were the coating consists of a water-insoluble film-former, a water-soluble polymer and eventually an acid-insoluble polymer incorporated therein.

Compounds of the formula ##STR1## wherein R.sub.1 is chlorine, bromine or alkyl of 1 to 3 carbon atoms;

4-Phenyl-4,5,6,7-tetrahydro-thieno(2,3-C)pyridines and salts thereof

Compounds of the formula ##STR1## wherein R.sub.2 is hydrogen, chlorine, bromine, formyl, acetyl, alkyl of 1 to 4 carbon atoms, nitro, cyano or --CH.sub.2 --A; where

4-Phenyl-4,5,6,7-tetrahydro-pyrrolo [2,3-c] pyridines and salts thereof

Compounds of the steroisomeric formulas ##STR1## wherein R.sub.1 and R.sub.2, which may be identical to or different from each other, are each phenyl, substituted phenyl, thienyl or furyl;

Growing community of inventors

Appenheim, Germany

Wolf D Bechtel